The Predatory Economics of Ozempic [tZzs9zEGeMZ]

The Predatory Economics of Ozempic [tZzs9zEGeMZ]

| 1h 28m 28s | Video has closed captioning.

Go to and start investing in your child today. Losing weight is mental as much as it is physical. But now, with a single injection, anyone can drop weight without having to change what they eat or how they live. With seemingly minimal side effects and impressive testimonials, weight loss drugs like Ozempic, Zepbound, Wegovy, and Mounjaro have become all the rage. Just like how tech startups have hitched their wagon to AI, drug manufacturers have hitched their valuations on obesity. But despite their altruistic missions and manufactured nobility, Big Pharma through history have demonstrated that they’re not to be trusted. As the opioid epidemic showed, if you give pharmaceutical companies an inch and they’ll take a mile. In their world, drugs are the hammer and everything is a nail. Their goal is to get as many people on as many drugs at as high of a dose and frequency as possible to keep profits up. If Big Pharma succeeds in classifying obesity as a disease just like Oxycontin once classified pain as a disease, they would be able to monetize the greatest patient pool in the world. As the testimonials have continued, the world has also forgotten that the manufacturers of these weight loss drugs are the same companies who endangered millions and killed thousands over decades with insulin price-gouging. In this episode, we’re diving into the dirty business of Big Pharma and weight loss drugs from the perspectives of the two biggest players, Eli Lilly and Novo Nordisk. ☕️ Support Modern MBA on Patreon: 💬 Join the Modern MBA community: 0:00 Unprecedented Virality 3:01 Sponsor Break (Fabric by Gerber Life) 5:00 Big Pharma Deconstructed 14:37 Eli Lilly 25:01 Novo Nordisk #mayo clinic keto acv gummies #keto carb pills #latest prescription diet pills #keto plus atv gummies